Key Players
Competitive Landscape
Hospital-at-home wearable biosensor market includes enterprise monitoring companies, wearable specialists and care platform providers. Philips and Masimo are expanding wearable and multiparameter monitoring, whereas Current Health and Biofourmis are focusing on patient enrollment, data review and clinical escalation. VitalConnect, VivaLNK, Dexcom and Biobeat offers cardiac, metabolic and hemodynamic sensing products. Hospitals compares intended use, measurement coverage, wear time, record connection, alert responsibility and replacement supply before selecting a product. Increasing product development and home-care partnerships is expected to support competition in the market.
Companies are increasingly focusing on acquisitions, partnerships and new monitoring functions in order to expand hospital-to-home applications. In August 2026, iRhythm agreed to acquire VitalConnect for about USD 287.5 million, adding multi-vital signs and hospital-to-home monitoring to its cardiac platform [20]. Philips added six wearable and out-of-hospital collaborations in August 2026 [21], while Current Health partnered with Cardinal Health in March 2026 for kit fulfillment, installation and retrieval [23]. In June 2026, Masimo received FDA clearance for respiratory-risk detection on Radius VSM [22]. Increasing company developments is expected to widen availability of wearable monitoring systems for supervised home care.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| In August 2026, iRhythm agreed to acquire VitalConnect for about USD 287.5 million. [20] | Cardiac monitoring companies are adding more patient measurements. | Acquisitions are combining ambulatory and hospital-to-home monitoring. | The combined products can support monitoring across more care settings. |
| In August 2026, Philips added six wearable and out-of-hospital technology collaborations. [21] | Hospitals requires continued patient observations beyond the bedside. | Hospital monitoring systems are adding third-party wearable devices. | Health systems can use different wearable sensors through one monitoring system. |
| In June 2026, Masimo received FDA clearance for respiratory-risk detection on Radius VSM. [22] | Clinical teams requires earlier identification of respiratory risk. | Wearable devices are adding functions for respiratory-risk detection. | Cleared detection functions can support monitored higher-acuity patients. |
| In March 2026, Current Health partnered with Cardinal Health for kit logistics. [23] | Hospital-at-home programs requires device setup, delivery and recovery. | Monitoring companies are adding kit delivery and retrieval support. | Hospitals can use one route for kit fulfillment, installation and retrieval. |
Source: Future Market Insights, Hospital-at-Home Wearable Biosensor Market Report, 2026-2036.
FMI data suggests public information does not establish one company as the verified market-share leader in the defined product market. Company position differs according to sensing range, hospital connection, home-care deployments and geographic presence.
Who leads the hospital-at-home wearable biosensor market?
Public information does not establish one company as the verified market-share leader in the defined product market. Company position differs according to sensing range, hospital connection, home-care deployments and geographic presence.
What should buyers evaluate before approving a supplier?
Hospitals evaluates intended use, measured parameters, patient eligibility, record connection, alert responsibility, cybersecurity, kit logistics and replacement supply before selecting a supplier. Wear time, connectivity recovery, cleaning and after-hours escalation are also checked during product use.
Which companies provide specialized sensing configurations?
Dexcom provides glucose sensing, whereas VitalConnect and VivaLNK offers wearable patch configurations. Masimo provides oxygenation and multiparameter monitoring, while Biobeat offers cuffless blood-pressure and hemodynamic measurements.
Which companies support broader hospital system connection?
Philips and GE HealthCare connects monitoring devices with hospital systems. Biofourmis and Current Health provides care platforms which combines device readings with patient enrollment, review and clinical escalation.
Representative Company Overview
| Company | Positioning | Verified market-relevant capability |
|---|---|---|
| Philips | Hospital monitoring and device integration | In August 2026, Philips added six wearable and out-of-hospital collaborators to its monitoring monitoring system. |
| Masimo | Wearable oxygenation and multiparameter monitoring | In June 2026, Masimo received FDA clearance for respiratory-risk detection on Radius VSM. |
| Biofourmis | Acute-care-at-home monitoring platform | In January 2025, AdventHealth selected Biofourmis for an acute-care-at-home program. |
| Medtronic | Hospital devices and transition monitoring | Its documented route includes partner-based wearable distribution for hospital-to-home monitoring. |
| VivaLNK | Wearable patch and clinician monitoring | Its documented hospital-at-home configuration combines patch sensing with clinician access. |
| Current Health | Connected wearable monitoring platform | In March 2026, Current Health partnered with Cardinal Health for kit fulfillment, installation, and retrieval. |
| VitalConnect | Wearable patch monitoring | In August 2026, iRhythm agreed to acquire VitalConnect for about USD 287.5 million. |
| GE HealthCare | Hospital monitoring systems | The company offers wireless patient monitoring products for hospital use, while home application depends on the selected product and program. |
| Dexcom | Continuous glucose monitoring | In April 2025, FDA clearance expanded the G7 15 Day adult glucose configuration. |
| Biobeat | Cuffless blood-pressure monitoring | Its portfolio includes cuffless blood-pressure and hemodynamic measurements for remote monitoring. |
Research Methodology
The company assessment includes suppliers offering wearable sensing, patient monitoring, hospital connection or care-at-home functions inside the defined market. Evidence is collected from government records, regulatory decisions, company information, product documents and official announcements. Company inclusion considers measured parameters, monitoring functions, home-care evidence, current developments and regional presence. Product approvals applies only to the named device and jurisdiction. Partnerships and acquisitions describes company activity and does not establish product performance or market leadership. Clinical services, standalone software, inpatient-only products and duplicate bundled revenue remains outside the product market. Segment shares and forecasts are proprietary estimates.
